Mg29 inhibitors represent a chemical class specifically aimed at modulating the function of the Mg29 protein, a component believed to play a crucial role in various cellular processes. The development of these inhibitors is a meticulous process that combines the precision of biochemical assays, the predictive power of computational modeling, and the nuanced insights gained from genetic manipulation. Initially, the identification of compounds with potential inhibitory effects on Mg29 begins with high-throughput chemical screening. This step involves testing a vast library of compounds to identify those that exhibit the ability to bind to and inhibit Mg29. The promising candidates from this screening are then subjected to rigorous molecular docking and dynamic simulation studies. These computational approaches offer detailed insights into how the inhibitors interact with Mg29, including the identification of binding sites, the strength of the inhibitor-protein interactions, and the conformational changes that occur upon binding. Such in-depth analyses are vital for understanding the mechanism of action of these inhibitors and for guiding the subsequent optimization of their chemical structures to enhance specificity and potency.
Following the computational and in vitro analyses, the selected Mg29 inhibitors are further evaluated in cellular models. Techniques such as CRISPR-Cas9 gene editing are employed to either overexpress or knock down Mg29 expression in these models, providing a controlled environment to assess the functional impact of the inhibitors under different levels of protein expression. Additionally, the use of fluorescently tagged Mg29 proteins enables real-time monitoring of the inhibitors' effects on the localization and function of Mg29 within the cell. This combination of genetic engineering and live-cell imaging techniques not only corroborates the findings from biochemical and computational studies but also provides a comprehensive view of the inhibitors' action in a biologically relevant context. Through these multifaceted approaches, the characterization of Mg29 inhibitors progresses, offering valuable insights into their interaction with the target protein and laying the groundwork for further refinement and study.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $223.00 $799.00 | 19 | |
Binds to ryanodine receptors in the SR, affecting calcium release and potentially impacting Mg29-related processes. | ||||||
Dantrolene | 7261-97-4 | sc-500165 | 25 mg | $350.00 | 7 | |
Inhibits ryanodine receptors, affecting calcium release from the SR, which could indirectly affect Mg29 function. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
A calcium channel blocker that affects calcium influx, potentially influencing Mg29-associated calcium signaling. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Another calcium channel blocker, impacts calcium dynamics in muscle cells, possibly affecting Mg29 function. | ||||||
Amlodipine | 88150-42-9 | sc-200195 sc-200195A | 100 mg 1 g | $74.00 $166.00 | 2 | |
Blocks calcium channels, altering calcium signaling which may indirectly influence Mg29 activity. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Stimulates calcium release from the SR, potentially affecting Mg29-mediated processes. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $28.00 $53.00 | 37 | |
Modulates store-operated calcium entry, potentially impacting Mg29-related signaling. | ||||||
Tetracaine | 94-24-6 | sc-255645 sc-255645A sc-255645B sc-255645C sc-255645D sc-255645E | 5 g 25 g 100 g 500 g 1 kg 5 kg | $66.00 $309.00 $500.00 $1000.00 $1503.00 $5000.00 | ||
Local anesthetic that can inhibit calcium release from the SR, possibly influencing Mg29 activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Inhibits the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), affecting calcium homeostasis in muscle cells. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $176.00 $624.00 | 3 | |
Inhibits SERCA, altering calcium dynamics in muscle cells, potentially impacting Mg29. | ||||||